- Home
- BCRX vs GLPG Comparison
BCRX vs GLPG Comparison
Compare BCRX & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- GLPG
- Stock Information
- Founded
- BCRX 1986
- GLPG 1999
- Country
- BCRX United States
- GLPG Belgium
- Employees
- BCRX N/A
- GLPG N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- BCRX Health Care
- GLPG Health Care
- Exchange
- BCRX Nasdaq
- GLPG Nasdaq
- Market Cap
- BCRX 1.7B
- GLPG 1.8B
- IPO Year
- BCRX 1994
- GLPG 2005
- Fundamental
- Price
- BCRX $9.97
- GLPG $25.32
- Analyst Decision
- BCRX Buy
- GLPG Sell
- Analyst Count
- BCRX 8
- GLPG 4
- Target Price
- BCRX $16.75
- GLPG $25.33
- AVG Volume (30 Days)
- BCRX 5.9M
- GLPG 466.6K
- Earning Date
- BCRX 05-05-2025
- GLPG 04-23-2025
- Dividend Yield
- BCRX N/A
- GLPG N/A
- EPS Growth
- BCRX N/A
- GLPG N/A
- EPS
- BCRX N/A
- GLPG N/A
- Revenue
- BCRX $503,485,000.00
- GLPG $311,493,731.00
- Revenue This Year
- BCRX $27.64
- GLPG N/A
- Revenue Next Year
- BCRX $13.42
- GLPG N/A
- P/E Ratio
- BCRX N/A
- GLPG N/A
- Revenue Growth
- BCRX 41.67
- GLPG 18.32
- 52 Week Low
- BCRX $5.06
- GLPG $22.36
- 52 Week High
- BCRX $11.11
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- BCRX 65.89
- GLPG 45.40
- Support Level
- BCRX $9.83
- GLPG $25.20
- Resistance Level
- BCRX $11.11
- GLPG $27.64
- Average True Range (ATR)
- BCRX 0.51
- GLPG 0.59
- MACD
- BCRX 0.20
- GLPG -0.09
- Stochastic Oscillator
- BCRX 68.33
- GLPG 23.93
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.